International Journal of Hematology

, Volume 109, Issue 6, pp 711–717 | Cite as

Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia

  • Takehiko MoriEmail author
  • Yasushi Onishi
  • Yukiyasu Ozawa
  • Chiaki Kato
  • Tatsuyuki Kai
  • Yoshinobu Kanda
  • Mineo Kurokawa
  • Masatsugu Tanaka
  • Takashi Ashida
  • Yasushi Sawayama
  • Takahiro Fukuda
  • Tatsuo Ichinohe
  • Yoshiko Atsuta
  • Hirohito Yamazaki
Original Article


Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) for hepatitis-associated aplastic anemia have not been fully evaluated. In the present study, the outcomes of 37 adult patients with hepatitis-associated aplastic anemia who underwent allogeneic HSCT were retrospectively analyzed using the registry database of Japan Society for Hematopoietic Cell Transplantation. The median age of the patients was 24 years (range, 16–61). The median period between diagnosis of hepatitis-associated aplastic anemia and HSCT was 6.0 months (range, 0.5–430.8). Stem cell sources were bone marrow (N = 19) or peripheral blood stem cells (N = 5) from an HLA-identical sibling or bone marrow (N = 11) and cord blood (N = 2) from an unrelated donor. The majority of conditioning regimens were fludarabine-based or high-dose cyclophosphamide-based. In all but 2 cases of early death, neutrophil engraftment was achieved. At the time of analysis, 32 patients were alive, with a median follow-up of 54.1 months. Five-year overall and failure-free survival rates were 86.0% (95% CI, 69.4–93.9%) and 75.0% (95% CI, 57.4–86.2%), respectively. Despite the heterogeneity in transplant procedures in a small number of patients, these results suggest that allogeneic HSCT is safe for use in hepatitis-associated aplastic anemia with a low rate of transplant-related mortality.


Hepatitis-associated aplastic anemia Allogeneic hematopoietic stem cell transplantation Conditioning Engraftment Transplant-related mortality 



The authors would like to thank all the physicians and data managers of each transplant center and the staff member of Japanese Data Center for Hematopoietic Cell Transplantation.

Compliance with ethical standards

Conflict of interest

Mineo Kurokawa receives consulting fees from Sanofi.k.k.


  1. 1.
    Brown KE, Tisdale J, Barrett AJ, Dunbar CE, Young NS. Hepatitis-associated aplastic anemia. N Engl J Med. 1997;336:1059–64.CrossRefGoogle Scholar
  2. 2.
    Rauff B, Idrees M, Shah SA, Butt S, Butt AM, Ali L, et al. Hepatitis-associated aplastic anemia: a review. Virol J. 2011;8:87.CrossRefGoogle Scholar
  3. 3.
    Gonzalez-Casas R, Garcia-Buey L, Jones EA, Gisbert JP, Moreno-Otero R. Systematic review: hepatitis-associated aplastic anaemia—a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther. 2009;30:436–43.CrossRefGoogle Scholar
  4. 4.
    Osugi Y, Yagasaki H, Sako M, Kosaka Y, Taga T, Ito T, et al. Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis-associated aplastic anemia. Haematologica. 2007;92:1687–90.CrossRefGoogle Scholar
  5. 5.
    Hayakawa J, Kanda J, Akahoshi Y, Harada N, Kameda K, Ugai T, et al. Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. Int J Hematol. 2017;105:578–86.CrossRefGoogle Scholar
  6. 6.
    Wang H, Tu M, Fu R, Wu Y, Liu H, Xing L, et al. The clinical and immune characteristics of patients with hepatitis-associated aplastic anemia in China. PLoS One. 2014;9:e98142.CrossRefGoogle Scholar
  7. 7.
    Witherspoon RP, Storb R, Shulman H, Buckner CD, Deeg HJ, Clift RA, et al. Marrow transplantation in hepatitis-associated aplastic anemia. Am J Hematol. 1984;17:269–78.CrossRefGoogle Scholar
  8. 8.
    Locasciulli A, Bacigalupo A, Bruno B, Montante B, Marsh J, Tichelli A, et al. Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party. Br J Haematol. 2010;149:890–5.CrossRefGoogle Scholar
  9. 9.
    Safadi R, Or R, Ilan Y, Naparstek E, Nagler A, Klein A, et al. Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantation. Bone Marrow Transplant. 2001;27:183–90.CrossRefGoogle Scholar
  10. 10.
    Atsuta Y. Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3–10.CrossRefGoogle Scholar
  11. 11.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefGoogle Scholar
  12. 12.
    Mori T, Koh H, Onishi Y, Kako S, Onizuka M, Kanamori H, et al. Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling. Int J Hematol. 2016;103:461–8.CrossRefGoogle Scholar
  13. 13.
    Mary JY, Baumelou E, Guiguet M. Epidemiology of aplastic anemia in France: a prospective multicentric study. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood. 1990;75:1646–53.Google Scholar
  14. 14.
    Liang DC, Lin KH, Lin DT, Yang CP, Hung KL, Lin KS. Post-hepatitic aplastic anaemia in children in Taiwan, a hepatitis prevalent area. Br J Haematol. 1990;74:487–91.CrossRefGoogle Scholar
  15. 15.
    Chen HF, Xu BX, Shen HS, Li ZY, Jin LJ, Tang JQ, et al. Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis-associated aplastic anemia. Drug Des Dev Ther. 2014;8:1299–305.CrossRefGoogle Scholar
  16. 16.
    Ohara A, Kojima S, Okamura J, Inada H, Kigasawa H, Hibi S, et al. Evolution of myelodysplastic syndrome and acute myelogenous leukaemia in children with hepatitis-associated aplastic anaemia. Br J Haematol. 2002;116:151–4.CrossRefGoogle Scholar
  17. 17.
    Pongtanakul B, Das PK, Charpentier K, Dror Y. Outcome of children with aplastic anemia treated with immunosuppressive therapy. Pediatr Blood Cancer. 2008;50:52–7.CrossRefGoogle Scholar
  18. 18.
    Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socie G, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94:1312–5.CrossRefGoogle Scholar
  19. 19.
    Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socie G, Maury S, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36:947–50.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Takehiko Mori
    • 1
    Email author
  • Yasushi Onishi
    • 2
  • Yukiyasu Ozawa
    • 3
  • Chiaki Kato
    • 4
  • Tatsuyuki Kai
    • 5
  • Yoshinobu Kanda
    • 6
  • Mineo Kurokawa
    • 7
  • Masatsugu Tanaka
    • 8
  • Takashi Ashida
    • 9
  • Yasushi Sawayama
    • 10
  • Takahiro Fukuda
    • 11
  • Tatsuo Ichinohe
    • 12
  • Yoshiko Atsuta
    • 13
    • 14
  • Hirohito Yamazaki
    • 15
  1. 1.Division of Hematology, Department of MedicineKeio University School of MedicineTokyoJapan
  2. 2.Department of Hematology and RheumatologyTohoku University HospitalMiyagiJapan
  3. 3.Department of HematologyJapanese Red Cross Nagoya First HospitalNagoyaJapan
  4. 4.Department of HematologyMeitetsu HospitalAichiJapan
  5. 5.Division of HematologyKita-Fukushima Medical CenterFukushimaJapan
  6. 6.Division of HematologyJichi Medical University Saitama Medical CenterSaitamaJapan
  7. 7.Department of Cell Therapy and Transplantation MedicineThe University of Tokyo HospitalTokyoJapan
  8. 8.Department of HematologyKanagawa Cancer CenterKanagawaJapan
  9. 9.Division of Hematology and Rheumatology, Department of Internal MedicineKindai University Faculty of MedicineOsakaJapan
  10. 10.Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine UnitNagasaki University HospitalNagasakiJapan
  11. 11.Hematopoietic Stem Cell Transplantation DivisionNational Cancer Center HospitalTokyoJapan
  12. 12.Department of Hematology and Oncology, Research Institute for Radiation Biology and MedicineHiroshima UniversityHiroshimaJapan
  13. 13.Japanese Data Center for Hematopoietic Cell TransplantationNagoyaJapan
  14. 14.Department of Healthcare AdministrationNagoya University Graduate School of MedicineNagoyaJapan
  15. 15.Division of Transfusion MedicineKanazawa University HospitalKanazawaJapan

Personalised recommendations